About ramucirumab
VEGFR-2-targeting monoclonal antibody
Used for
- Advanced stomach or gastroesophageal junction cancer, alone or with chemotherapy
- Metastatic colorectal cancer, with chemotherapy
- Advanced non-small-cell lung cancer, with docetaxel
- Advanced liver cancer after sorafenib treatment
Usual adult dose
Usually 8 mg/kg intravenously every two weeks for stomach or liver cancer; other cancers use different schedules and combinations.
Common side effects
- High blood pressure
- Fatigue and weakness
- Diarrhea
- Low blood-cell counts or bleeding
Important warnings
- Can cause serious bleeding, blood clots, or gastrointestinal perforation.
- May impair wound healing; treatment is withheld around major surgery.
- Monitor blood pressure and urine protein during treatment.
- Infusion reactions can occur; treatment requires supervised intravenous administration.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for three months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for three months after the last dose.
Interactions
- No major direct drug interactions are established; chemotherapy combinations can increase toxicity.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.